Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression

@article{Cheon2015StauntoniaH,
  title={Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression},
  author={Yoon-Hee Cheon and J. Baek and Sun-Hyang Park and Sung-Jun Ahn and Myeung-Su Lee and Jaemin Oh and Ju-Young Kim},
  journal={BMC Complementary and Alternative Medicine},
  year={2015},
  volume={15}
}
BackgroundNatural plants, including common vegetables and fruits, have been recognized as essential sources for drug discovery and the development of new, safe, and economical medicaments. Stauntonia hexaphylla (Lardizabalaceae) is widely distributed in Korea, Japan, and China, and is a popular herbal supplement in Korean and Chinese folk medicine owing to its analgesic, sedative, and diuretic properties. However, the exact pharmacological effects of S. hexaphylla extract, particularly its… Expand
Transcriptome Analysis Reveals That Abeliophyllum distichum Nakai Extract Inhibits RANKL-Mediated Osteoclastogenensis Mainly through Suppressing Nfatc1 Expression
TLDR
The findings show that the extract of A. distichum efficiently suppressed osteoclastogenesis by regulating osteOClast-related genes, thus offering a novel therapeutic strategy for osteoporosis. Expand
The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
TLDR
The results indicate that the use of S. hexaphylla extract in BPH is probably beneficial through 5α-reductase inhibition and α-adrenergic receptor blockade, which can be concluded to have a therapeutic effect on BPH. Expand
Dendrobium moniliforme Exerts Inhibitory Effects on Both Receptor Activator of Nuclear Factor Kappa-B Ligand-Mediated Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Bone Erosion in Vivo
TLDR
Investigating the relationship between DM and osteoclasts found that DM significantly reduced receptor activator of nuclear factor kappa-B ligand (RANKL)-induced tartrate-resistant acid phosphatase (TRAP)-positive osteoclast formation and had a beneficial effect on lipopolysaccharide-mediated bone erosion. Expand
Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression
TLDR
It is shown that an ethyl acetate fraction from the shiitake mushroom, Lentinula edodes, inhibited RANKL-induced osteoclast differentiation by blocking the NFATc1 signaling pathway, and treatment of LEA rescued an osteoporotic phenotype in a zebrafish model of glucocorticoid-induced arthritis. Expand
Antipostmenopausal effects of Stauntonia hexaphylla and Vaccinium bracteatum fruit combination in estrogen-deficient rats
TLDR
Investigating the mitigation of menopausal symptoms, such as hot flushes and postmenopausal osteoporosis after combinatorial treatment with SH and VB of ovariectomized (OVX) rats provides the foundation for developing SHVB as a natural substance to replace hormones in the future. Expand
The chemical constituents of ethanolic extract from Stauntonia hexaphylla leaves and their anti-inflammatory effects
TLDR
Results suggest that S. hexaphylla leaves and compound 1 are useful candidates for treating inflammatory and other diseases. Expand
Bioactive triterpene glycosides from the fruit of Stauntonia hexaphylla and insights into the molecular mechanism of its inflammatory effects.
TLDR
Compounds 6 and 10 contributed to the anti-inflammatory effects of S. hexaphylla fruit, which could be developed as a natural nutraceutical and functional food ingredient. Expand
Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis
TLDR
It is demonstrated that SC extract protects against BPH by inhibiting 5α-reductase type 2 and inducing prostate cell apoptosis and might be useful in the clinical treatment of BPH. Expand
Assortment of Stauntonia hexaphylla and Cornus officinalis protect against testosterone-induced benign prostatic hyperplasia through anti-inflammatory and anti-proliferative activity
TLDR
It is demonstrated that SC extract attenuates BPH through anti-proliferative and anti-inflammation activities and might be useful in the clinical treatment of BPH. Expand
Isolation, structural elucidation, and insights into the anti-inflammatory effects of triterpene saponins from the leaves of Stauntonia hexaphylla.
TLDR
This is the first comprehensive study of saponins from the leaves of S. hexaphylla based on anti-inflammatory extract screening guidelines, and suggested that compound 13 isolated from S. Hexaphyella might be useful for treating inflammation. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases.
TLDR
An overview on the key molecules, which (could) serve as promising targets for novel therapeutic interventions with the aim of enhancing osteoblast formation or suppressing osteoclast development, is given. Expand
Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo
TLDR
Selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption, and significantly reduced the severity of collagen-induced arthritis in mice. Expand
Signaling crosstalk between RANKL and interferons in osteoclast differentiation
TLDR
The series of in vivo experiments revealed that these two distinct IFN-mediated regulatory mechanisms are both important to maintain homeostasis of bone resorption, and may offer a molecular basis for the treatment of bone diseases. Expand
PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2.
TLDR
It is shown that NFATc1 upregulation is dependent on RANKL-mediated phosphorylation of PLCgamma2 downstream of Dap12/Fc receptor gamma (Dap12 /FcRgamma) receptors and is blocked by the PLCGamma inhibitor U73122. Expand
RANKL Stimulates Inducible Nitric-oxide Synthase Expression and Nitric Oxide Production in Developing Osteoclasts
TLDR
Preventing RANKL-induced NO (via iNOS-selective inhibition or use of marrow cells from iN OS–/– mice) increased osteoclast formation and bone pit resorption, indicating that such NO normally restrains RankL-mediated osteOClastogenesis. Expand
Ca2+‐NFATc1 signaling is an essential axis of osteoclast differentiation
TLDR
Osteoclasts are unique, multinucleated giant cells that decalcify and degrade the bone matrix and respond to the change in [Ca2+]o by increasing the intracellular Ca2+, which regulates diverse cellular functions. Expand
Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment
TLDR
The results suggest that Fos plays essential roles in the upregulation of RANK expression in osteoclast precursors within the bone environment. Expand
Osteoclastogenesis, Bone Resorption, and Osteoclast‐Based Therapeutics
TLDR
This review focuses on key advances in understanding of molecular mechanisms underlying the formation, function, and survival of osteoclasts, including key signals mediating osteoclast differentiation, including PU.1, RANK, CSF‐1/c‐fms, and src. Expand
Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
TLDR
There is still no prospective, placebo-controlled study with a sufficient number of patients that demonstrates that long-term parenteral calcitonin administration reduces the risk of osteoporotic fractures, and a possible effect of calcitonine to enhance bone quality, which cannot be assessed by routinely available methods. Expand
NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1*
TLDR
It is concluded that NF-κB controls early osteoclast differentiation from precursors induced directly by RANKL and TNF, leading to activation of c-Fos followed by NFATc1. Expand
...
1
2
3
4
...